PMGC Holdings subsidiary NorthStrive amends YuvaBio deal for three-phase expansion
PMGC Holdings, via subsidiary NorthStrive Biosciences, entered a First Amendment with Yuva Biosciences on Aug 27, 2026 to launch a three-phase Expansion Program advancing up to four AI-discovered compounds toward lead nomination.
PMGC Holdings, through its subsidiary NorthStrive Biosciences, entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on Aug 27, 2026. The amendment starts a three-phase Expansion Program aimed at advancing up to four AI-discovered compounds toward lead nomination.